AU · rank #3 · 2026-07-22
TOI
NASDAQ · $535M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.908 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.06 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $235,110 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $8.40 | +54.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +52.71% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 5.00 |
| Gross margin TTM | +15.1% |
| 52w high | $6.67 |
| Market cap (USD) | $535M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
TOI is a value-based community oncology operator with clinics across five states, a growing specialty pharmacy, and meaningful exposure to Medicare Advantage and CMS oncology models.
Rationale
The setup fits analyst_upside because analysts are highly positive with 54.7% upside, unanimous revision agreement, recent target raises, and the company is backing that up with strong Q1 revenue growth, a narrower loss, and improved liquidity after refinancing.
Material risks
- 1TOI’s biggest thesis risk is reimbursement and policy sensitivity in capitated oncology and CMS value-based programs, which could quickly pressure margins and cash flow.
- 2The new $75 million term loan and continued GAAP losses keep leverage and refinancing risk in play if growth or specialty pharmacy momentum slows.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.